NCT01234545

Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors

A Prospective Observational Study on the Home Treatment of Haemarthrosis With rFVIIa (Activated Recombinant Factor VII) in Haemophilia A and B Patients With Inhibitors

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 35 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: Male
• Age: 2 Years
• Healthy volunteers: Not accepted

Summary

This trial is conducted in Africa and Asia. The aim of this study is to evaluate the efficacy of home treatment of joint bleeds (haemarthrosis) with NovoSeven® (activated recombinant human factor VII) in patients with haemophilia A and B patients with inhibitors.

Conditions

• Congenital Bleeding Disorder
• Haemophilia A
• Haemophilia B

Interventions

Type	Name	Description
DRUG	activated recombinant human factor VII	Prescription is done at the discretion of the prescribing physician as part of normal clinical routine

Timeline

• Start date: 2010-10-01
• Primary completion: 2012-04-01
• Completion: 2012-04-01
• First posted: 2010-11-04
• Last updated: 2014-11-14

Locations

5 sites across 5 countries: Algeria, Morocco, Oman, Saudi Arabia, United Arab Emirates